Navigation Links
Deston Therapeutics Stands By Safety and Efficacy of Auralgan After FDA Action
Date:2/25/2011

nally, numerous health organizations and institutions have stated that Auralgan is safe and effective.  The United States National Library of Medicine's Medline Plus and the National Institute of Health's National Center for Biotechnology Information have stated on their webpages that Auralgan is a safe and effective treatment for ear pain and inflammation associated with AOM.  The American Academy of Pediatric and American Academy of Family Physicians along with the Institute for Clinical Systems Improvement published guidances recognizing Auralgan as a safe and effective treatment for ear pain in pediatric patients with AOM.

According to Mr. Preston, when Deston acquired Auralgan, it believed that this product qualified as an "old drug" because of the long marketing of Auralgan, the evidence supporting its safe and effective use, and the fact that the Federal Government has never concluded that it was a "new drug" or took action against the previous manufacturer of Auralgan.  

Deston was unaware that FDA believed that Auralgan was a "new drug" until the FDA informed Deston of this position last year.  In response to this information, Deston's legal counsel prepared and filed, on May 28, 2010, a "Citizen Petition" with the FDA, to make the case, point by point, why Auralgan was not a 'new drug'. Deston had expected a due process period whereby FDA would provide an in-kind formal response, explaining why they believed it was a 'new drug'.

Deston also began discussions with FDA regarding how to obtain FDA approval for Auralgan if, after addressing the Citizen Petition, the FDA decided the product qualified as a "new drug."  On February 15, 2011 – a day after the Federal Government seized Auralgan – Deston received a partial response to its Citizen Petition implying that the FDA has not yet made a determination on whether Auralgan qualifies as a "new drug" or an "old drug."  Because FDA has yet to review
'/>"/>

SOURCE Deston Therapeutics LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015  Today the U.S. Food ... Bexsero® for the prevention of serogroup B meningococcal ... and Pfizer,s vaccine Trumenba®, which received FDA approval in ... this devastating disease. "I have heard ...
(Date:1/23/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/5dh22x/urinary_catheters ) ... Market (Indwelling or Foley Catheters, Intermittent Catheters and Male ... Share, Growth, Trends and Forecast 2014 - 2020" ... present, the global market for urinary catheters is experiencing ...
(Date:1/23/2015)...  Northwest Biotherapeutics, Inc. (NASDAQ: NWBO )("NW Bio"), a ... and inoperable solid tumor cancers, announced today that CEO ... Annual Phacilitate Immunotherapy Forum in Washington D.C. ... place on January 26 at 10:30 a.m. EST at the ...
Breaking Medicine Technology:The National Meningitis Association (NMA) Applauds FDA Approval of Second Vaccine To Protect Against Serogroup B Meningococcal Disease 2Urinary Catheters Market (Indwelling or Foley Catheters, Intermittent Catheters and Male External or Condom Catheters) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Urinary Catheters Market (Indwelling or Foley Catheters, Intermittent Catheters and Male External or Condom Catheters) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 2NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 3
... , EAST BRUNSWICK, N.J., Nov. 25 Swissray International, ... ) systems, announced today that its operations have been acquired ... towards growing Swissray,s medical imaging brand. The acquisition included all ... After 25 years of success and growth Swissray is now ...
... , CHAPEL HILL, ... Prabhavathi Fernandes, president and chief executive officer, will present at ... a.m. EST, December 1, 2009, at The New York Palace ... an overview of the company,s two leading antibiotic clinical programs ...
Cached Medicine Technology:Swissray International Announces New Ownership 2
(Date:1/22/2015)... The Incredible Bulk is a revolutionary method put ... muscle by up to 30lbs in less than 12 weeks ... Stan Stevenson, prompting an investigative review. , “Our Incredible ... diet formula that allows the body to pack on a ...
(Date:1/22/2015)... Minn. (PRWEB) January 22, 2015 Blue Cross ... those Minnesotans who exemplify what it means to “Live Fearless.” ... chance for people to share their stories about how they ... or simply inspired others by living in the moment. By ...
(Date:1/22/2015)... The federal court overseeing thousands of vaginal mesh ... District of West Virginia has upheld a $2 million verdict ... trial. In an Order dated January 21st, the Court denied ... C.R. Bard had not proven a miscarriage of justice. (Cisson ...
(Date:1/22/2015)... Dallas, TX (PRWEB) January 22, 2015 ... the issue of experience and person-centeredness in the long-term ... moving towards action across the continuum. The paper, “The ... the Continuum,” engages perspectives and practices of the patient, ...
(Date:1/22/2015)... 22, 2015 Autocarinsurancebest.com has released a new ... commercial auto insurance policy . , Auto insurance quotes ... It is no longer necessary to call an agent or ... available online on a single website: http://autocarinsurancebest.com/ . , ...
Breaking Medicine News(10 mins):Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Commercial Auto Insurance Provides Several Important Features! 2
... shown to boost vitamin D levels and now researchers ... Higher sun exposure during childhood and early adolescence is ... to the study. ,Australian investigators conducted a study in ... a high prevalence of multiple sclerosis. //Researchers surveyed 136 ...
Indian shopkeepers reported a plunge in sales of Coca-Cola and Pepsi soft drinks Friday and some put out banners to deter buyers in a growing scare after an environment group said the beverages contai...
... are prepared for human consumption may be needed to fight ... in hundreds of thousands of people, it was claimed last ... yet between a disease commonly found in livestock and Crohn's ... one in 600 of the population. ,Prof Hermon-Taylor ...
... majority of the public still does not know cholesterol can ... American Heart Association believes the public has to know high ... to improve the educational process. ,Heart disease is the leading ... from heart disease have dropped in the last 20 years, ...
... worsen acne! ,Acne is a condition of the skin ... up to 25 percent of adults. ,While stress has ... claims have been unsubstantiated until now. Twenty-two university students ... academic examination within the time of the study.// Exam ...
... Mothers around the world will be pleased with a new ... The study, conducted by researchers at the Chinese University of ... verbal memory than their peers without training. ,Researchers put ... of memory tests. The boys had to recall words from ...
Cached Medicine News:
80 inch PVC tubing with connectors and 19 gauge straight, beveled cannula. Fits Bausch & Lomb Surgical cassettes. Allows the safe removal of silicone oil in 10 minutes or less. 3/Box...
... gauge, 25 mm cannula with 30 gauge, 4.76 ... mm flattened tip. Cannula is attached to a ... ID x 8 inch long), for use with ... other vitreo-retinal membranes using visco elastic materials. Flattened, ...
20 gauge x 25 mm cannula with 30 degree x 5 mm tip. 30 gauge cannula extends into hub 2 mm from end of hub. 10 per box....
Developed for oculoplastic procedures for corneal and scleral protection. Dimensions enable protector to rest on the sclera and not on the cornea. Easily removed with Bishop-Harmon Forceps. Individua...
Medicine Products: